Goldman Sachs
ZBIO

Goldman Sachs’s Zenas BioPharma ZBIO Stock Holding History

Goldman Sachs’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.46M Buy
381,461
+250,763
+192% +$5.63M ﹤0.01% 3318
2025
Q4 		$4.75M Buy
+130,698
New +$4.3M ﹤0.01% 3793
2025
Q2 		– Sell
-23,957
Closed -$189K – 6526
2025
Q1 		$189K Sell
23,957
-18,217
-43% -$143K ﹤0.01% 5655
2024
Q4 		$345K Sell
42,174
-90,226
-68% -$1.41M ﹤0.01% 5435
2024
Q3 		$2.24M Buy
+132,400
New +$2.38M ﹤0.01% 4064

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Goldman Sachs's ZBIO Position: Q1 2026 in Review

Goldman Sachs increased its Zenas BioPharma (ZBIO) stake by 192% in Q1 2026, buying an estimated $5.63M and bringing the position to 381,461 shares worth $7.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3318.

Goldman Sachs first reported a position in ZBIO in Q3 2024 and has held it in 5 quarters since. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Goldman Sachs held 381,461 shares of Zenas BioPharma worth $7.46M as of Q1 2026.
  • Goldman Sachs bought 250,763 Zenas BioPharma shares in Q1 2026, an estimated $5.63M.
  • Zenas BioPharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3318 holding.
  • Goldman Sachs first reported a position in Zenas BioPharma in Q3 2024 and has held it in 5 quarters since.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.